News

Last month, March 2025, the CGTLive® team was diligently tracking the FDA's activities related to the development of cell and gene therapies for the treatment of…

Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

AbstractClinical genetic testing often takes days to weeks, but rapid, affordable tests during outpatient visits could significantly benefit patients. This is…

"More than a century ago, Dr. Alois Alzheimer described the brain changes in a younger woman who had passed away from what we now call Alzheimer's disease,"…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…

“The symptoms are sometimes vague and they often mimic other conditions like cancer, neuropathic conditions and heart disease,” says Dr. Keyur Shah.Abnormal…

Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…